Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8987236 | 0.87 | LTB4R (0.67) | LTB4RLTB4R2 | |
| SCHEMBL8987435 | 0.81 | LTB4R (0.69) | LTB4R | |
| SCHEMBL4348705 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9520945 | 0.80 | LTB4R (0.56) | LTB4RLTB4R2 | |
| Ammonia Solution, Strong SCHEMBL6757534 | 0.79 | LTB4R (0.73) | LTB4RLTB4R2 | |
| SCHEMBL8987246 | 0.78 | LTB4R (0.65) | LTB4RLTB4R2 | |
| SCHEMBL6757532 | 0.76 | LTB4R (0.69) | LTB4RLTB4R2 | |
| SCHEMBL8987117 | 0.75 | LTB4R (0.71) | LTB4R | |
| SCHEMBL6760742 | 0.75 | LTB4R (1.00) | LTB4R | |
| SCHEMBL6759758 | 0.75 | LTB4R (0.67) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | claimed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | claimed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | LTB4R 8/4885LTB4R2 7/4885 |
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | LTB4R 8/4885LTB4R2 4/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | LTB4R 8/4885LTB4R2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.